Related Experiment Video
Updated: Aug 14, 2026
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 29, 2010
Prognostic value of lymph node involvement in ovarian serous borderline tumors
Benedicte Lesieur1, Aminata Kane, Pierre Duvillard
1Department of Gynecologic Surgery, Institut Gustave Roussy, Villejuif, France.
Objective:
This study was conducted to evaluate the prognosis value of lymph node involvement (LN positive) lymph node involvement for borderline ovarian tumor (BOT).
Study Design:
This was a retrospective study on 49 patients treated at our institution for advanced-stage serous BOT (International Federation of Gynecology and Obstetrics [FIGO] III or IV). Pathological characteristics and survival were compared according to the lymph node status. The same analysis was performed on 1503 patients of the Surveillance, Epidemiology, and End Results (SEER) database.
Results:
In our institution, 14 patients were LN positive. Eight patients have been upstaged after lymph node dissection. No patient has died during follow-up (median 53 months). LN positivity was not associated with recurrence. In the SEER registry, 93 patients (6.2%) had LN positivity. These patients were younger and with more advanced local extension. Survival curves were similar after adjustment for FIGO stage.
Conclusion:
Lymph node involvement does not appear as a prognosis factor for advanced-stage BOT.
